Movement disorders News and Research

RSS

Clinical trial of gene transfer therapy for advanced Parkinson's disease

Henry Ford West Bloomfield Hospital is embarking on a research study for advanced Parkinson's disease using a state-of-the-art treatment called gene transfer.

7 Oct 2009

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Data results published this month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals' NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity.

7 Oct 2009

Butler Hospital leads clinical study for effectiveness and safety of DBS for OCD

Butler Hospital in Providence, R.I., is leading a clinical study evaluating the effectiveness and safety of deep brain stimulation (DBS) for severe obsessive-compulsive disorder (OCD).

6 Oct 2009

NIH awards $10.5 million grant for OCD treatment research

A new research center exploring the science underlying a potential new treatment for obsessive-compulsive disorder has been established at the University of Rochester Medical Center, thanks to a $10.5 million award from the National Institute of Mental Health.

1 Oct 2009

Coenzyme Q10 to slow down the effects of Parkinson's disease?

Rush University Medical Center is participating in a large-scale, multi-center clinical trial in the U.S. and Canada to determine whether a vitamin-like substance, in high doses, can slow the progression of Parkinson's disease, a neurodegenerative disorder that affects about one million people in the United States.

22 Sep 2009

Neurodegenerative disorders are the second-leading cause of early-onset dementia, says report

Neurodegenerative disorders called frontotemporal dementias (FTD) are the second-leading cause of early-onset dementia in persons under age 65 and can emerge sometimes as early as age 20.

21 Sep 2009

Spinal implant developed by Sanfor Clinic neurosurgeon receives FDA market clearance

Sanford Health, a comprehensive health care provider in the Upper Midwest, announced today a spinal implant developed by Sanford Clinic Neurosurgeon, Wilson Asfora, MD, Sanford Clinic Neurosurgery & Spine, has received United States Food and Drug Administration (FDA) 510(k) market clearance as a lumbar intervertebral body fusion device.

31 Aug 2009

FDA provides marketing clearance for the spinal implant developed by Sanford Health

28 Aug 2009

Two-photon microscopy technique tracks calcium levels in mice neurons

For over a century, scientists have been using electrical stimulation to explore and treat the human brain. The technique has helped identify regions responsible for specific neural functions-for instance, the motor cortex and pleasure center-and has been used to treat a variety of conditions from Parkinson's disease to depression.

27 Aug 2009

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.

26 Aug 2009

Study reveals that increased neurostimulation market offers growth for device industries

The device industry would do well to focus on the treatment needs of individuals suffering from nerve-related disorders as implanted technologies that deliver electrical stimulation begin to supplant drugs for treating certain nerve-related disorders.

24 Aug 2009

Possible neurological complications of heart surgery detailed in new report

In the most comprehensive and up-to-date review of its kind, researchers list possible nervous system complications of bypass surgeries, aortic surgery, cardiac catheterizations, valve replacements, heart transplants and surgeries for congenital heart disease and heart tumors.

13 Aug 2009

Neurological complications of heart surgery detailed in research

Possible neurological complications of heart surgery, ranging from headaches to strokes, are detailed in a new report in the online journal MedLink Neurology.

13 Aug 2009

New clues about the roots of neurological disease

Switching off a key DNA repair system in the developing nervous system is linked to smaller brain size as well as problems in brain structures vital to movement, memory and emotion, according to new research led by St. Jude Children's Research Hospital scientists.

27 Jul 2009

Deep brain stimulation for psychiatric disorders

Pioneering therapeutic trials to investigate the effectiveness of deep brain stimulation (DBS) in hard-to-treat depression, obsessive-compulsive disorder (OCD) and Tourette's syndrome are underway at multiple medical centers around the world, according to a review in the June 2009 issue of Mayo Clinic Proceedings.

30 Jun 2009

Telemedicine expands reach of care for Parkinson’s patients

A unique and innovative telemedicine project is providing distant nursing home patients with Parkinson's disease access to neurologists at the University of Rochester Medical Center (URMC).A pilot study of the project - the results of which were released this month at the International Congress of Parkinson's Disease and Movement Disorders in Paris - demonstrates that the system can improve the quality of life and motor function of patients.

17 Jun 2009

Biovail acquires worldwide rights to Tetrabenazine

Biovail Corporation today announced a wholly owned subsidiary has entered into a definitive agreement to acquire worldwide development and commercialization rights to the entire portfolio of tetrabenazine products, including Xenazine/Nitoman (tetrabenazine tablets), and the associated intellectual property rights held by Cambridge Laboratories (Ireland) Ltd and its affiliates.

18 May 2009